Search research articles
Contact Us
Filters
Showing results (101-110 of 113) with videos related to
Page
of 12
Sort By:
Lancet (London, England)
|
July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
Toni K Choueiri, Robert W Ross, Susanna Jacobus, et al.
The Journal of Urology
|
April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
Adam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W Ryan, Ofer Merimsky, Mark Agulnik, et al.
Cancer
|
January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
Walter M Stadler, Robert A Figlin, David F McDermott, et al.
Lancet (London, England)
|
June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Clinical Genitourinary Cancer
|
August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
Brian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Cancer
|
March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 113) with videos related to
Sort By:
Page
of 12
Lancet (London, England)
|
July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
Toni K Choueiri, Robert W Ross, Susanna Jacobus, et al.
The Journal of Urology
|
April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study
Adam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2016
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W Ryan, Ofer Merimsky, Mark Agulnik, et al.
Cancer
|
January 19, 2010
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
Walter M Stadler, Robert A Figlin, David F McDermott, et al.
Lancet (London, England)
|
June 24, 2019
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D Tap, Hans Gelderblom, Emanuela Palmerini, et al.
Clinical Genitourinary Cancer
|
August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
Brian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Cancer
|
March 25, 2021
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
Michael R Harrison, Brian A Costello, Nrupen A Bhavsar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2024
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer
Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Page
of 12